PharmaLogic, a speciality nuclear pharmacy business, has agreed to acquire a controlling interest in Agilera Pharma, a radiopharmaceutical manufacturing company based in Norway, for an undisclosed price.
The move forms part of PharmaLogic’s broader strategy to establish a fully integrated global contract development and manufacturing organisation (CDMO) focused on radiopharmaceutical therapeutics.
The majority stake will be purchased from Norway’s Institute for Energy Technology (IFE), which founded Agilera as a subsidiary in 2023.
Agilera currently employs 140 people and operates three business segments, including clinical-stage development, commercial manufacturing and wholesale distribution of radiopharmaceuticals.
The firm is licensed by the Norwegian Medicines Agency and maintains GMP certification, enabling its participation in both domestic and international radiopharmaceutical supply chains.
Agilera’s manufacturing infrastructure is said to have supported the commercial delivery of over 600,000 therapeutic doses across more than 40 countries.
Its production network spans the US, Europe and Asia, and the company has been a longstanding development and manufacturing partner for major pharmaceutical organisations.
IFE CEO Nils Morten Huseby said: “For IFE, the sale of a majority stake in Agilera marks a significant achievement as the largest commercialisation effort carried out from the Institute to date. As a leading Research Institute, IFE is committed to innovation and job creation and has played a key role in the development and manufacturing of radiopharmaceutical therapeutics through Agilera.
“The entry of PharmaLogic as a new majority shareholder in Agilera will enable rapid scale-up, growth and development of Agilera’s operations to meet the increased demand for radiopharmaceutical therapeutics globally.”
The acquisition will see Agilera’s operations integrated into PharmaLogic’s existing radiopharmaceutical manufacturing platform.
According to the agreement, PharmaLogic intends to invest in the expansion of Agilera’s contract development and manufacturing capabilities. The company aims to enhance Agilera’s infrastructure and scale its operations to address increasing demand for radiopharmaceutical therapeutics.
PharmaLogic president Etienne Montagut said: “PharmaLogic’s acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field.
“By combining our expertise with Agilera’s industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments.”
The planned transaction remains subject to regulatory approvals, transfer of licences and other closing conditions. Completion is anticipated in June 2025. Solomon Partners Securities advised PharmaLogic on the deal.
